Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Kidney360 Année : 2023

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial

Résumé

Background: SGLT2 inhibitors, originally developed as glucose-lowering agents for treatment of type 2 diabetes, have been shown to have cardio-and kidney protective effects among chronic kidney disease (CKD) patients with and without diabetes. However, the mechanisms remain largely unknown. Methods: DECODE-CKD is an investigator-initiated, prospective, single-center, randomized, placebocontrolled trial evaluating the effects of 6 months of treatment with 10 mg of dapagliflozin compared with placebo on cardiac structure and function in 222 adults with CKD. The primary objective is to assess whether dapagliflozin improves LV mass index. Secondary and exploratory endpoints include changes in cardiac-and kidney markers, quality of life, depressive symptoms, and cognitive function. Conclusion: This is the first study to address the effects of SGLT2 inhibitors on cardiac structure and function in patients with CKD. The results will provide valuable insights into the mechanisms underlying the cardioprotective benefits of SGLT2 inhibitors in patients with CKD.
Fichier principal
Vignette du fichier
Effects_of_Dapagliflozin_on_EChOcardiographic.8.pdf (230.54 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04025795 , version 1 (13-03-2023)

Licence

Paternité

Identifiants

Citer

Katja Vu Bartholdy, Niklas Dyrby Johansen, Nino Landler, Kristoffer Grundtvig Skaarup, Jesper Jensen, et al.. Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial. Kidney360, 2023, 4 (2), pp.143-149. ⟨10.34067/KID.0006982022⟩. ⟨hal-04025795⟩
21 Consultations
27 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More